The creation and production of gene treatments, particularly AAV vectors, depend heavily on bioprocessing. The term "bioprocessing" describes the process of creating medicinal goods using biological systems, such as living cells or organisms. In the case of AAV vectors, bioprocessing involves the cultivation of cells that are used to produce the viral vectors.
A bioprocessing technology that can be used to enhance the manufacturing procedure is a scalable suspension platform for AAV production. Bioreactors, which are vessels that offer a controlled environment for cell growth, are generally used in this technology. Suspension culture can be accommodated in bioreactor designs, allowing cells to develop in a liquid media without adhering to a surface. Suspended culture enables better cell density in a smaller volume, increasing AAV vector yields.
Adeno-associated virus (AAV) gene therapy vector production can be scaled up and made more effective with the use of a device called a scalable suspension platform. AAVs are tiny viruses that have the potential to transport genes, making them an effective treatment for a range of genetic diseases.
AAVs have traditionally been created using adherent culture systems, which take up a lot of room and are challenging to scale up. This issue is addressed by the creation of a scalable suspension platform for AAV manufacture, which offers a more effective and scalable way of production.
Using bioreactors and specific conditions to encourage AAV growth and replication in suspension culture are standard components of this method. Manufacturers can reduce the volume of cells needed for manufacturing by adopting suspension culture to boost cell density in a smaller area. Suspension culture also makes scaling up simpler because it enables for bigger bioreactors to accommodate demand.
Bioprocessing technologies for AAV manufacturing may also include specialised media, bioreactor design, and downstream processing methods in addition to suspension culture. Purification and isolation of the AAV vectors from the production system are steps in downstream processing. Several chromatography techniques, filtration, and other purification techniques may be used for this.
Gene therapy vector production could undergo a revolution with the creation of a scalable suspension platform for AAV manufacturing, making them more widely available and reasonably priced for patients in need. With this method, new gene therapies could be developed and commercialised more quickly, allowing for the quicker introduction of effective treatments to patients.
Want to find out more? Join industry experts on March 28–29, 2023 at the Steigenberger Airport Hotel, Berlin, Germany as they discuss Scalable suspension platform for AAV manufacturing.
To register or learn more about the Forum please check here: https://bit.ly/3zxguXW.
For more information and group participation, contact us: [email protected]
